R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

G Held; B Altmann; A Kerkhoff; T Gastinne; T Weber; RO Casasnovas; H Tilly; MG Da Silva; J Hoffmann; S Tonino; S Vigouroux; M Dreyling; V Safar; M Andre; S Mayer; F Morschhauser; P Feugier; CW Scholz; A Dabrowska-Iwanicka; P Gaulard; TJ Molina; A Rosenwald; R Greil; U Jaeger; A Avigdor; L Thurner; S Maurer; M Löffler; M Ziepert; C Haioun; V Poeschel; R Houot

doi:10.1182/blood-2023-172951

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

G Held, B Altmann, A Kerkhoff, T Gastinne, T Weber, RO Casasnovas, H Tilly, MG Da Silva, J Hoffmann, S Tonino, S Vigouroux, M Dreyling, V Safar, M Andre, S Mayer, F Morschhauser, P Feugier, CW Scholz, A Dabrowska-Iwanicka, P GaulardTJ Molina, A Rosenwald, R Greil, U Jaeger, A Avigdor, L Thurner, S Maurer, M Löffler, M Ziepert, C Haioun, V Poeschel, R Houot

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

3 Citations (Web of Science)

Original language	English
Journal	BLOOD
Volume	142
DOIs	https://doi.org/10.1182/blood-2023-172951
Publication status	Published - 2023
Event	65th Annual Meeting of the American-Society-of-Hematology (ASH) - San Diego, United States Duration: 9 Dec 2023 → 12 Dec 2023

Access to Document

10.1182/blood-2023-172951

Cite this

Held, G., Altmann, B., Kerkhoff, A., Gastinne, T., Weber, T., Casasnovas, RO., Tilly, H., Da Silva, MG., Hoffmann, J., Tonino, S., Vigouroux, S., Dreyling, M., Safar, V., Andre, M., Mayer, S., Morschhauser, F., Feugier, P., Scholz, CW., Dabrowska-Iwanicka, A., ... Houot, R. (2023). R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG. BLOOD , 142. https://doi.org/10.1182/blood-2023-172951

Held, G ; Altmann, B ; Kerkhoff, A et al. / R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG. In: BLOOD 2023 ; Vol. 142.

@article{43b2113550f64a38bce403420c723c78,

title = "R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG",

author = "G Held and B Altmann and A Kerkhoff and T Gastinne and T Weber and RO Casasnovas and H Tilly and {Da Silva}, MG and J Hoffmann and S Tonino and S Vigouroux and M Dreyling and V Safar and M Andre and S Mayer and F Morschhauser and P Feugier and CW Scholz and A Dabrowska-Iwanicka and P Gaulard and TJ Molina and A Rosenwald and R Greil and U Jaeger and A Avigdor and L Thurner and S Maurer and M L{\"o}ffler and M Ziepert and C Haioun and V Poeschel and R Houot",

year = "2023",

doi = "10.1182/blood-2023-172951",

language = "English",

volume = "142",

journal = "BLOOD ",

issn = "0006-4971",

publisher = "American Society of Hematology ",

note = "65th Annual Meeting of the American-Society-of-Hematology (ASH) ; Conference date: 09-12-2023 Through 12-12-2023",

}

Held, G, Altmann, B, Kerkhoff, A, Gastinne, T, Weber, T, Casasnovas, RO, Tilly, H, Da Silva, MG, Hoffmann, J, Tonino, S, Vigouroux, S, Dreyling, M, Safar, V, Andre, M, Mayer, S, Morschhauser, F, Feugier, P, Scholz, CW, Dabrowska-Iwanicka, A, Gaulard, P, Molina, TJ, Rosenwald, A, Greil, R, Jaeger, U, Avigdor, A, Thurner, L, Maurer, S, Löffler, M, Ziepert, M, Haioun, C, Poeschel, V & Houot, R 2023, 'R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG', BLOOD , vol. 142. https://doi.org/10.1182/blood-2023-172951

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG. / Held, G; Altmann, B; Kerkhoff, A et al.
In: BLOOD , Vol. 142, 2023.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

AU - Held, G

AU - Altmann, B

AU - Kerkhoff, A

AU - Gastinne, T

AU - Weber, T

AU - Casasnovas, RO

AU - Tilly, H

AU - Da Silva, MG

AU - Hoffmann, J

AU - Tonino, S

AU - Vigouroux, S

AU - Dreyling, M

AU - Safar, V

AU - Andre, M

AU - Mayer, S

AU - Morschhauser, F

AU - Feugier, P

AU - Scholz, CW

AU - Dabrowska-Iwanicka, A

AU - Gaulard, P

AU - Molina, TJ

AU - Rosenwald, A

AU - Greil, R

AU - Jaeger, U

AU - Avigdor, A

AU - Thurner, L

AU - Maurer, S

AU - Löffler, M

AU - Ziepert, M

AU - Haioun, C

AU - Poeschel, V

AU - Houot, R

PY - 2023

Y1 - 2023

U2 - 10.1182/blood-2023-172951

DO - 10.1182/blood-2023-172951

M3 - Abstract (Journal)

SN - 0006-4971

VL - 142

JO - BLOOD

JF - BLOOD

T2 - 65th Annual Meeting of the American-Society-of-Hematology (ASH)

Y2 - 9 December 2023 through 12 December 2023

ER -

Held G, Altmann B, Kerkhoff A, Gastinne T, Weber T, Casasnovas RO et al. R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG. BLOOD . 2023;142. doi: 10.1182/blood-2023-172951